Vevoctadekin

维沃他德白介素

Report date: 2026/03/11 20:02:12

Base Information

Drug NameVevoctadekin
Drug Alias Namedecoy-resistant Interleukin-18 variantST-067DR-18
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin 18 receptor agonists
TargetsInterleukin 18 receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSimcha IL-18 Inc
China Registration ClassN/A

Develop Information

Active CompaniesSimcha TherapeuticsSimcha IL-18 Inc
Inactive CompaniesUniversity Of Washington
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[11] 
Inactive IndicationsMultiple MyelomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A